Nitrofurazone
Actin-n, Furacin (nitrofurazone) is a small molecule pharmaceutical. Nitrofurazone was first approved as Actin-n on 1982-01-01. It is used to treat burns, clostridium infections, escherichia coli infections, proteus infections, and staphylococcal skin infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nitrofurazone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACTIN-N | Sherwood Medical | N-017343 DISCN | 1982-01-01 | 1 products |
| FURACIN | Shire | N-005795 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B05: Blood substitutes and perfusion solutions
— B05C: Irrigating solutions, blood substitutes and perfusion
— B05CA: Antiinfective irrigating solutions
— B05CA03: Nitrofural
D: Dermatologicals
— D08: Antiseptics and disinfectants
— D08A: Antiseptics and disinfectants
— D08AF: Nitrofuran derivatives, antiseptics and disinfectants
— D08AF01: Nitrofural
— D09: Medicated dressings
— D09A: Medicated dressings
— D09AA: Medicated dressings with antiinfectives
— D09AA03: Nitrofural
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01C: Agents against leishmaniasis and trypanosomiasis
— P01CC: Nitrofuran derivatives, antiprotozoal drugs
— P01CC02: Nitrofural
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AX: Other antiinfectives in atc
— S01AX04: Nitrofural
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA02: Nitrofural
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | — | 1 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular atrophy | D009133 | HP_0003202 | — | 3 | 2 | — | — | — | 3 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 3 | 2 | — | — | — | 3 |
| Atrophy | D001284 | — | — | 3 | 2 | — | — | — | 3 |
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 1 | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Spinal muscular atrophies of childhood | D014897 | Orphanet_83419 | G12.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunotherapy | D007167 | — | — | — | — | — | — | 3 | 3 |
| Melanoma | D008545 | — | — | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 2 | 2 |
| Metagenome | D054892 | — | — | — | — | — | — | 2 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 2 | 2 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
| High-throughput nucleotide sequencing | D059014 | — | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | — | — | 1 | 1 |
| Pilonidal sinus | D010864 | HP_0010769 | L05 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nitrofurazone |
| INN | nitrofural |
| Description | Nitrofurazone (INN, trade name Furacin) is an antimicrobial organic compound belonging to the nitrofuran class. It is most commonly used as a topical antibiotic ointment. It is effective against gram-positive bacteria, gram-negative bacteria, and can be used in the treatment of trypanosomiasis. Its use in medicine has become less frequent, as safer and more effective products have become available. Nitrofurazone is listed under California Prop 65, and has demonstrated clear evidence to be mutagenic and carcinogenic during animal studies, and has been discontinued for human use in the USA. The substance is pale yellow and crystalline. It was once widely used as an antibiotic for livestock.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1 |
Identifiers
| PDB | — |
| CAS-ID | 59-87-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL869 |
| ChEBI ID | — |
| PubChem CID | 1839 |
| DrugBank | DB00336 |
| UNII ID | X8XI70B5Z6 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,044 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
65 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use